FT576 in Subjects With Multiple Myeloma

What's the purpose of the trial?

To evaluate the safety and tolerability of FT576 when administered as monotherapy and in combination with daratumumab.

Trial status

Accepting patients

Phase 1
Last Updated
3 months ago
Am I Eligible

Participating Centers

There are 15 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Daratumumab is a type of cancer drug called a monoclonal antibody. Daratumumab attaches to a protein called CD38, which is present in high numbers on the surface of multiple myeloma cells, as well as on certain other types of cells, such as red blood cells.
  • FT576 is an investigational, universal, off-the-shelf NK cell cancer immunotherapy.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients


Accepting patients

FT576 + Daratumumab

Not yet accepting

FT576 (Fractionated Dosing)

Published Results

Explore published results and other resources associated with this clinical trial (including press releases, news articles and videos).

Interim Phase I Clinical Data of FT576 As Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma

Results: As of a data cutoff date of 18 Jul 2022, 9 patients with R/R MM were treated and evaluable for safety and efficacy, in the first 2 dose levels of Regimen A (n = 6) and in the first dose level of Regimen B (n = 3). No dose-limiting toxicities, and no events of any grade of cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome, or graft-versus-host disease (GvHD), were observed.

Conclusions: Administration of a single dose of FT576 at 100 or 300 million cells/dose alone or in combination with daratumumab is safe and well tolerated thus far without CRS, neurotoxicity, or GvHD. Interim clinical data, including safety and tolerability and initial anti-tumor activity, from the ongoing Phase I dose-escalation study of FT576 will be presented at the conference.

1 year ago Read more

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.